Merck (MRK.N) said it has commercially launched in China the world’s first single fixed‑dose long‑acting RSV monoclonal antibody for prevention of RSV‑caused lower respiratory tract infection in newborns and infants entering or born into their first RSV season. The product is administered as a single fixed dose without weight‑based dosing.

2026-09-09

Merck (MRK.N) said it has commercially launched in China the world’s first single fixed‑dose long‑acting RSV monoclonal antibody for prevention of RSV‑caused lower respiratory tract infection in newborns and infants entering or born into their first RSV season. The product is administered as a single fixed dose without weight‑based dosing.